Top

Published in:

01-09-2018 | Urologic Oncology

Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer

Authors: Neelam Mukherjee, PhD, Robert Svatek, MD, MSCI

Published in: Annals of Surgical Oncology | Issue 9/2018

Excerpt

Bacillus Calmette–Guérin (BCG) immune therapy is used for (1) preventing bladder cancer relapse following complete tumor excision of Ta and T1 papillary tumors, and (2) eradication of carcinoma in situ (CIS), which is not usually completely removed due to its diffuse and often multifocal involvement of the bladder. Tumors that relapse despite adequate BCG are often aggressive and life-threatening if not managed appropriately. Thus, radical cystectomy is the gold standard for BCG failures. Alternatives to cystectomy include intravesical valrubicin, which is US FDA-approved for BCG-unresponsive CIS and off-label approaches, including repeat instillation of BCG with or without interferon-α, or intravesical instillation of other immune or chemotherapeutic agents. Currently, a major obstacle in this field is the lack of understanding of immune regulatory pathways driving BCG responsiveness, making it difficult to understand why many patients do not respond to therapy. …

Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887–95.PubMedPubMedCentralCrossRef

Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.CrossRefPubMed

Leach DR, Krummel MK, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.CrossRefPubMed

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.CrossRefPubMedPubMedCentral

Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365–9.CrossRefPubMed

Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, Shibayama S, et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol. 2009;182(11):6682–9.CrossRefPubMed

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.CrossRefPubMed

Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201–17.CrossRefPubMedPubMedCentral

Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428–1433.CrossRefPubMed

10.

Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162(3):313–25.CrossRefPubMed

11.

Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93.CrossRefPubMedPubMedCentral

12.

Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68–83.PubMed

13.

Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499–505.CrossRefPubMed

14.

Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 Expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158–67.CrossRefPubMed

15.

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, et al. PD-1, PD-L1 Protein expression in non-small cell lung cancer and their relationship with tumor-infiltrating lymphocytes. Med Sci Monit. 2017;23:1208–16.CrossRefPubMedPubMedCentral

16.

Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–25.CrossRefPubMedPubMedCentral

17.

Grillo F, Pigozzi S, Ceriolo P, Calamaro P, Fiocca R, Mastracci L. Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections. Histochem Cell Biol. 2015; 144(1):93–9.CrossRefPubMed

18.

Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, et al. Once BCG unresponsive, always BCG unresponsive: an open letter to the FDA to enhance recruitment into clinical trials in bladder cancer. Bladder Cancer. 2017;3(3):145–6.CrossRefPubMedPubMedCentral

Title: Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer
Authors: Neelam Mukherjee, PhD
Robert Svatek, MD, MSCI
Publication date: 01-09-2018
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 9/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-018-6610-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2018

Screening Mammography: Getting to Version 2.0

MelMART Trial: It’s Now or Never

Why Do Reoperation Rates Vary So Much After Lumpectomy for Breast Cancer? Examining the Reoperation Puzzle at the Massachusetts General Hospital

Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach

Intraoperative Nomograms, Based on One-Step Nucleic Acid Amplification, for Prediction of Non-sentinel Node Metastasis and Four or More Axillary Node Metastases in Breast Cancer Patients with Sentinel Node Metastasis

A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01)